Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Vistagen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.08), Fidelity Earnings reports.

Shares of VTGN opened at $0.65 on Friday. The stock’s 50-day simple moving average is $0.72 and its 200 day simple moving average is $0.79. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.14 and a quick ratio of 1.14. Vistagen Therapeutics has a 52-week low of $0.29 and a 52-week high of $1.66.

Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN bought a new position in shares of Vistagen Therapeutics in the second quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in Vistagen Therapeutics during the 3rd quarter worth approximately $65,000. D.A. Davidson & CO. lifted its stake in Vistagen Therapeutics by 27.3% in the 3rd quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after purchasing an additional 22,500 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after purchasing an additional 35,729 shares in the last quarter. Institutional investors and hedge funds own 8.57% of the company’s stock.

Several research analysts recently commented on VTGN shares. ValuEngine downgraded shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 27th. Chardan Capital reissued a “neutral” rating on shares of Vistagen Therapeutics in a report on Monday, December 2nd. Finally, William Blair cut shares of Vistagen Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 14th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $2.35.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: Accumulation/Distribution

Earnings History for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.